UK Medical Devices Agency (MDA) plans to manage increased demands
This article was originally published in Clinica
The UK's Medical Devices Agency expects a rise of 25% in 1996/97 in demands for clinical investigations which it will handle within the statutory deadline of 60 days. An expected increase in vigilance activities will also challenge the Agency, which predicts that the number of vigilance reports will double.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.